American Academy of Neurology

April 2010
BioWorld Today;4/15/2010, Vol. 21 Issue 72, p4
The article reports that UCB Pharma Inc. is negotiating with the U.S. Food and Drug Administration (FDA) to make Neupro, a rotigotine transdermal system, to be available to patients with early state Parkinson's disease as soon as possible.


Related Articles

  • Keppra gains pediatric indication.  // Drug Topics;7/11/2005, Vol. 149 Issue 13, p6 

    Reports that the U.S. Food and Drug Administration has approved UCB Pharma Inc.'s anti-epilepsy drug, Keppra, to be used as add-on therapy in the treatment of partial-onset seizures in children.

  • Recently Approved.  // Pharmaceutical Representative;Nov2006, Vol. 36 Issue 11, p14 

    The article presents several drugs that are recently approved by the Food and Drug Administration in the U.S. It includes Fentora (fentanyl buccal tablet) from Cephalon Inc. to reduce pain in the opioid therapy of cancer patients, GlaxosmithKline PLC's Lamictal (lamotrigine) tablets as...

  • Keppra approved in oral formulation.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p14 

    Reports on the approval of the U.S. Food and Drug Administration to UCB Pharma Inc.'s Keppra oral solution. Use of Keppra in treating patients with epilepsy; Administration of Keppra oral solution; Safety and efficacy of the drug for the treatment of epilepsy.

  • Pipeline.  // Medical Marketing & Media;May2009, Vol. 44 Issue 5, p10 

    The article offers news briefs related to the U.S. Food and Drugs Administration (FDA) and various drug industry in the U.S. The Keppra XR of UCB Pharma Inc. has received a new dosage strength from FDA, which will allow doctors to decrease the number of the patient's dosage. The FDA has...

  • Applications Update.  // PharmaWatch: Biotechnology;Dec2005, Vol. 4 Issue 12, p11 

    The article presents developments related to the pharmaceutical industry. Biothera has filed an investigational new drug application with the U.S Food & Drug Administration (FDA) for its drug Imprime PGG for the treatment of cancer. The FDA plans to complete its review of a marketing submission...

  • UCB GETS POSITIVE RESULTS FROM TWO CIMIZIA PHASE III STUDIES.  // Worldwide Biotech;Feb2007, Vol. 19 Issue 2, p2 

    The article reports that UCB got positive results for signs and symptoms from two Cimzia phase III studies in the treatment of rheumatoid arthritis. UCB has also received a complete response letter from the U.S. Food and Drug Administration requesting additional information and clarification on...

  • FDA ACCEPTS XYREM SNDA FOR REVIEW.  // Biotech Business;May2005, Vol. 18 Issue 5, p2 

    Reports on the decision of the U.S. Food and Drug Administration to accept for filing the Supplemental New Drug Application (sNDA) of Orphan Medical Inc. for its Xyrem(R) (sodium oxybate) oral solution. Marketing strategy for Xyrem; Target diseases for treatment using Xyrem; Fee received by...

  • NEWSLINE.  // Monthly Prescribing Reference;Jul2010, Vol. 26 Issue 7, pA.20 

    The article offers updates related to the pharmaceutical industry in the U.S. The Food & Drug Administration (FDA) has revised labelling of the long-acting beta agonist (LABA)- containing respiratory medications. Vimpat, lacosamide, an adjunct treatment of partial-onset seizures in patients...

  • Parkinson's Disease Update.  // PharmaWatch: CNS;May2008, Vol. 7 Issue 5, p5 

    The article offers news briefs related to the treatment of Parkinson's disease in the U.S. Solvay Pharmaceuticals announces that the Food and Drug Administration (FDA) has granted them fast track designation to the development program for levodapa and carbidopa to cure motor fluctuations. UCB...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics